Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitors (106):

Cat. No.	Product Name	Effect	Purity

HY-N0499

Cyanidin Chloride	Inhibitor	99.43%
Cyanidin Chloride (IdB 1027) is an orally active antioxidant and enzyme inhibitor. Cyanidin Chloride has IC₅₀ values of 90 μM and 60 μM against PGHS-1 and PGHS-2, respectively. Cyanidin Chloride exhibits excellent antioxidant and anti-inflammatory activities, scavenges free radicals, inhibits lipid peroxidation, and protects DNA from cleavage. Cyanidin Chloride can be used in the research of inflammatory diseases.

HY-W017428

4-Ethoxybenzaldehyde	Inhibitor	99.67%
4-Ethoxybenzaldehyde (P-Ethyoxybenzaldehyde) is a derivative of benzaldehyde. 4-Ethoxybenzaldehyde can significantly inhibit the production of key inflammatory factors such as prostaglandin E2 (PGE2), IL-6, and IL-8 induced by ultraviolet radiation (UVR). 4-Ethoxybenzaldehyde shows significant efficacy and good safety in reducing facial redness when added to an oil-in-water emulsion at a concentration of 1%. 4-Ethoxybenzaldehyde can be used in the study of chronic inflammatory skin diseases.

HY-133079

Ascorbyl tetra-2-hexyldecanoate	Inhibitor	98.0%
Ascorbyl tetra-2-hexyldecanoate (tetra-isopalmitoyl Ascorbic acid; IPAA) is a lipophilic derivative of vitamin C (L-ascorbic acid). Ascorbyl tetra-2-hexyldecanoate (100 μM ) can prevent the decrease in viability of HaCaT keratinocytes induced by UVB, hydrogen peroxide, or tert-butyl hydroperoxide, and reduce the production of IL-1α and prostaglandin E2 (PGE2). Topical application of ascorbyl tetra-2-hexyldecanoate (1%) increases epidermal viability thickness, stratum corneum water content, and skin smoothness, and reduces skin roughness in hairless mice. Ascorbyl tetra-2-hexyldecanoate can be used to develop skin whitening agents in the beauty industry.

HY-101813

Laflunimus	Inhibitor	99.70%
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC₅₀ values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.

HY-106067A

Dazoxiben hydrochloride	Inhibitor	99.90%
Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor.

HY-N0677

Dehydroandrographolide succinate	Inhibitor	99.88%
Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED₅₀ = 386.9 mg/kg) by decreasing TXB₂ levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways.

HY-15342A

Timapiprant sodium	Inhibitor	99.61%
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP₂, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [³H] PGD2 from human recombinant DP₂ (K_i=13 nM), rat recombinant DP₂ (K_i=3 nM), and human native DP₂ (K_i=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils.

HY-130223

11β-Prostaglandin E2	Inhibitor	99.9%
11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [^3H]PGE₂ binding to hypothalamic membranes in the rat with a K_i of 53.3 nM.

HY-B1074

Ethamsylate	Inhibitor	99.49%
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..

HY-E70127

Serratiopeptidase	Inhibitor
Serratiopeptidase (Brasan; Dasen) is an orally active zinc-containing metalloprotease belonging to the serralysin family. Serratiopeptidase reduces the release of inflammatory mediators such as prostaglandins, thromboxanes and interleukins by inhibiting COX, thereby relieving pain, swelling and redness. Serratiopeptidase exhibits antibiofilm, mucolytic and wound-healing activities. As a serine protease, Serratiopeptidase has the ability to dissolve blood clots, fibrin and atherosclerotic plaques. Serratiopeptidase degrades amyloid fibrils and has potential anti-Alzheimer's effects. Serratiopeptidase shows cytotoxicity against colon cancer cells.

HY-124404

12(R)-HETE	Inhibitor	99.90%
12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation.

HY-106080A

Furegrelate sodium	Inhibitor	99.69%
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent.

HY-W009706

Alclofenac	Inhibitor	99.44%
Alclofenac (Allopydin) is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica.

HY-101438

Darbufelone	Inhibitor	99.49%
Darbufelone is a dual inhibitor of cellular PGF_2α and LTB₄ production. Darbufelone potently inhibits PGHS-2 (IC₅₀= 0.19 μM) but is much less potent with PGHS-1 (IC₅₀=20 μM).

HY-138665

HHS-0701	Inhibitor	98.90%
HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.

HY-17357S

Nepafenac-d₅	Inhibitor	98.84%
Nepafenac-d₅ (AHR-9434-d₅; AL-6515-d₅) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.

HY-N10225

Thielavin A	Inhibitor	98.5%
Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration.

HY-17477

Guacetisal	Inhibitor	98.87%
Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.

HY-107345

Droxicam	Inhibitor	99.59%
Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253). Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse.

HY-109877

Ro 22-3581	Inhibitor	99.91%
Ro 22-3581 (4'-(Imidazol-1-yl) acetophenone) is a selective thromboxane (Tx) synthetase inhibitor.

Name
Email *

	Sorry, but the email address you supplied was invalid.